Tanweer S Khan, 44San Antonio, TX

2022028, Sep 8, 2022

May 18, 2020

17/611553

- Rahway NJ, US
Jason E. Imbriglio - Bridgewater NJ, US
Angela D. Kerekes - Plainfield NJ, US
Tanweer Khan - Bridgewater NJ, US
Claire Lankin - Highbridge NJ, US
Derun Li - West Roxbury MA, US
Zhicai Wu - Montvale NJ, US
Yusheng Xiong - Plainsboro NJ, US
Hyewon Youm - Berkeley Heights NJ, US
Yang Yu - Edison NJ, US
Feng Ye - Scotch Plains NJ, US
Anthappan Tony Kurissery - Bangalore, IN
Venukrishnan Komanduri - Manchester, GB

Merck Sharp Dohme Corp. - Rahway NJ

C07D 491/107
A61K 45/06
C07D 401/14
C07D 413/14

The present invention relates to Compounds of Formula I: I and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment or prophylaxis of cardiometabolic diseases including high blood pressure, heart failure, kidney disease, and diabetes in a subject.

2022027, Sep 1, 2022

May 18, 2020

17/611540

- Rahway NJ, US
Jason E. Imbriglio - Bridgewater NJ, US
Angela D. Kerekes - Plainfield NJ, US
Tanweer Khan - Bridgewater NJ, US
Claire Lankin - Highbridge NJ, US
Derun Li - West Roxbury MA, US
Rui Liang - East Brunswick NJ, US
Pengcheng Patrick Shao - Fanwood NJ, US
Zhicai Wu - Montvale NJ, US
Yusheng Xiong - Plainsboro NJ, US
Feng Ye - Scotch Plains NJ, US
Hyewon Youm - Berkeley Heights NJ, US
Yang Yu - Edison NJ, US
Anthappan Tony Kurissery - Bangalore, IN
Venukrishnan Komanduri - Manchester, GB

Merck Sharp Dohme Corp. - Rahway NJ

A61K 31/54
C07D 495/04
C07D 519/00
C07D 513/04
A61K 31/4545
A61K 31/438
A61K 31/444

The present invention relates to Compounds of Formula I: I and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment of cardiometabolic diseases including high blood pressure, heart failure, kidney disease, and diabetes in a subject.

2018003, Feb 8, 2018

Feb 1, 2016

15/549242

- Rahway NJ, US
Rongze Kuang - Green Brook NJ, US
Yeon-Hee Lim - Piscataway NJ, US
Michael Man-Chu Lo - Bedminister, NJ
Pauline C. Ting - New Providence NJ, US
Purakkattle Biju - Piscataway NJ, US
Manuel de Lera Ruiz - Perkasie PA, US
Sylvia J. Degrado - Scotch Plains NJ, US
Alexander L. Tung - Bensalem PA, US
Timothy J. Henderson - Natick MA, US
Liwu Hong - East Brunswick NJ, US
Jae-Hun Kim - Scotch Plains NJ, US
Dong Won-Shik Kim - Rockville MD, US
Joe Lee - Rahway NJ, US
Jie Wu - Scotch Plains NJ, US
Heping Wu - Edison NJ, US
Yushi Xiao - Rahway NJ, US
Tao Yu - Edison NJ, US
Gang Zhou - Bridgewater NJ, US
Xiaohong Zhu - Edison NJ, US
Kevin D. McCormick - Basking Ridge NJ, US
Jayaram R. Tagat - Westfield NJ, US
Dong Xiao - Warren NJ, US
Tanweer Khan - Bridgewater NJ, US
Jianhua Cao - Edison NJ, US
Michael Berlin - Rahway NJ, US
Yonglian Zhang - Metuchen, NJ

Merck Sharp & Dohme Corp. - Rahway NJ

C07D 239/84
C07D 401/14
C07D 413/12
C07D 417/12
C07D 405/12
C07D 417/14
C07D 413/14
C07D 471/04
C07D 401/12
C07D 403/12

The present invention is directed to compounds of generic formula I: or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist.

2016001, Jan 21, 2016

Mar 11, 2014

14/774200

Tanweer A. KHAN - Kenilworth NJ, US
Jack D. SCOTT - Kenilworth NJ, US
Jared N. CUMMING - Kenilworth NJ, US
- Rahway NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

C07D 285/18
C07D 417/12

In its many embodiments, the present invention provides certain S-imino-S-oxo iminothiadiazine compounds, including compounds Formula (I): or a tautomers and/or stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomeros and said stereoisomers, wherein R, R, R, R, R, ring A, R, m, L, and Rare as defined herein. The novel compounds of the invention are useful as BACE inhibitors and may be useful for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.

2015017, Jun 25, 2015

Jul 18, 2013

14/415759

- Rahway NJ, US
Tanweer A. Khan - Westfield NJ, US

C07D 487/04

The present invention is directed to novel substituted dihydropyrrolopyrazoles of structural Formula I which are inhibitors of the dipeptidyl peptidase-N enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase IV enzyme is involved.